Transcript Systemic Enzyme Formulation Functions

Systemic Enzyme Therapy:
Anti-Inflammatory & Anti-Aging
Applications
By:
Joseph J Collins, RN, ND
Naturopathic Consultant
Presented at:
17th ANNUAL WORLD CONGRESS ON
ANTI-AGING MEDICINE
& REGENERTIVE BIOMEDICAL
TECHNOLOGIES
Las Vegas, Nevada, USA
Dec. 9 – 12, 2009
Main Stage, Saturday 9:30 a.m.
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
1
Objectives, Disclaimer, Copyright & Permissions
1. Review biomarkers of inflammation that have systemic affects
on diverse body systems.
2. Review mediators of inflammation.
3. Understand the mechanisms of action by which systemic
enzyme therapy with Wobenzym® decreases mediators of
inflammation.
4. Understand clinical applications for systemic enzyme therapy
with Wobenzym® as they relate to degenerative diseases and
progression of senescence.
References: Each slide has its own numbered references in the Notes Page view of the presentation.
Disclaimers: This presentation is for Educational Purposes Only. The entire contents of this presentation, are for informational purposes only.
The contents are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your
physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional
medical advice or delay in seeking it because of something you have read in this presentation. These statements made in this presentation have
not been evaluated by the Food and Drug Administration and are not intended to be used to diagnose, treat, cure or prevent any diseases. The
Content is the opinion of the author, and does not represent the opinion of any other party.
Copyright & Permissions: This entire presentation and all images herein are copyright of Joseph J Collins and SystemicEnzymeSupport.org.
This presentation may be used for scientific, clinical and patient education in its entirety without editing or modification.
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
2
What is Systemic Enzyme Therapy?
Systemic Enzyme Therapy (also called Systemic
Enzyme Support) is a treatment modality that uses
Wobenzym® formulations to increase serum levels
of proteolytic enzymes, which in turn activate α-2macroglobulin - a serum protein that facilitates the
binding and removal of foreign peptides, excessive
inflammatory mediators and auto-toxic
endogenous proteins - and thereby support
balanced humoral immune function and modulate
systemic inflammation.
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
3
BIOMARKERS OF INFLAMMATION
• Increased Erythrocyte Sedimentation Rate
• Increased C-Reactive Protein
• Abnormal Immunoglobulins Levels (IgG, IgE, IgA, IgM)
• Increases Circulating Immune Complexes
• Increase Cytokine Production with an Imbalance of Cytokines
• Increased Fibrin Activation & Fibrosis [(Prothrombin Time (PT)]
• Increased Amyloid Production & Deposition
Other Mediator of inflammation:
• Damaged Proteins and Cellular Debris
(glycosylated, oxidized , and other auto-toxic endogenous proteins)
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
4
Erythrocyte Sedimentation Rate
ESR:
In RA patients free of overt arterial disease, there is a
direct relationship between cumulative
inflammatory burden (ESR area-under-the-curveyears) & arterial stiffness.[1]
Systemic Enzyme Therapy:
Erythrocyte Sedimentation Rate
(ESR) is lowered in RA patients
treated with Wobenzym® N and
Wobenzym® PS.[2,3,4]
Wobenzym® formulations lowered ESR levels in relapsing urinary
tract infections, adnexitis , and acute trauma.[5,6,7]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
5
C-Reactive Protein
C-Reactive Protein
Elevated CRP levels are a marker of systemic
inflammation that is associated with not only
cardiovascular disease, but also dementia, pulmonary
disease and lymphatic dysfunction.[1,2,3]
Systemic Enzyme Therapy:
In lymphedema patients on Wobenzym®,
there was a mean percent change of
CRP from baseline of –39.8% compared
to –17.4% in the placebo group.[3]
Wobenzym® also lowered CRP levels in rheumatoid arthritis
and acute trauma.[4,5]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
6
Abnormal Immunoglobulins Levels
Abnormal Immunoglobulins Levels
Elevated Immunoglobulins occur in neurodegenerative diseases such as Alzheimer’s
(high Iga), as well as atopic dermatitis,
recurrent infections, & rheumatoid arthritis.[1,2,3,4]
Systemic Enzyme Therapy:
Wobenzym® PS therapy resulted in
normalization of IgA in 60 % of recurrent
infection patients and reduction of
primarily elevated IgE levels in 93 % of
patients. [3]
Wobenzym® lowers autoimmune antibodies in autoimmune
diseases such as rheumatoid arthritis and eczema. [2,4]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
7
Circulating Immune Complexes
Circulating Immune Complexes
Elevated CIC are contributory to the progression
of liver disease, atherosclerosis, complications for
diabetes, myocardial re-infarction, atopic
dermatitis, rheumatoid arthritis, Behcet's disease,
and other immune complex diseases.[1,2,3,4,5,6,7,8,9]
Systemic Enzyme Therapy:
Wobenzym® decreased CIC levels an
additional 45% when used as an adjuvant
(with methotrexate) in rheumatoid arthritis.[8]
Wobenzym® lowered CIC levels in patients with liver disease,
diabetes, myocardial infarction, atopic dermatitis & Behcet's
disease.[1,2,3,4,5,6,7,9]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
8
Imbalance of Cytokines
Imbalance of Cytokines
Increased pro-inflammatory cytokines
(Th1) contribute to the progression
degenerative diseases such as
rheumatoid arthritis, while excessive
TGF-beta (a Th2 cytokine) is seen in
many inflammatory disorders
(pulmonary fibrosis, cataracts, &
certain cancers).[1,2,3]
Systemic Enzyme Therapy:
In clinical studies, Wobenzym® therapy
decreased excessive pro-inflammatory
cytokines (IL-1b and TNF-alpha in RA
patients, while in other studies it
decreased excessive TGF-beta.[4]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
9
Increased Fibrin Activation & Fibrosis
Increased Fibrin Activation & Fibrosis
Increased fibrin activation and/or fibrosis is found
in a number of acute & degenerative conditions
including phlebitis, rheumatoid arthritis and some
cancers.[1,2,3]
Systemic Enzyme Therapy:
In postphlebitic syndrome, the effect of
Wobenzym® PS therapy was more
pronounced (84% vs 73% for conventional
therapy) due to increased blood fibrinolytic
activity and inhibited platelet function.[1]
Both increased blood fibrinolytic activity and increased
proteolysis of extravascularly deposited fibrin are observed in a
number of clinical conditions treated with Wobenzym® .[1,2,3,4,5,6,7,8]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
10
Increased Amyloid Production & Deposition
Increased Amyloid Production & Deposition
Accumulation of beta-amyloid peptide in the
brain plays a central role in the development
and progression of Alzheimer’s disease
(AD).[1,2,3]
Systemic Enzyme Therapy:
Wobenzym® activates alpha-2macroglobulin and its receptor,
low density lipoprotein receptorrelated protein (LRP), which
function together to facilitate the
cellular uptake and degradation
of -amyloid peptide. [1,2,3]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
11
Damaged Proteins and Cellular Debris
Damaged Proteins and Cellular Debris
The formation of toxic protein aggregates is a common
denominator to many neurodegenerative diseases and
aging. Accumulation of toxic, possibly infectious protein
aggregates induces a cascade of events, such as
excessive inflammation, the production of reactive oxygen
species, apoptosis and neuronal loss.[1]
Systemic Enzyme Therapy:
Wobenzym® activation of α2M modulates a
potent chaperone-like action of α2M that has
broad specificity for proteins partly unfolded as
a result of heat or oxidative stress. α2M patrols
extracellular spaces for unfolded/misfolded
proteins and facilitate their disposal.[1,2]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
12
Mediators of Inflammation
EXOGENOUS MEDIATORS OF INFLAMMATION
Bacterial, viral, parasitic, fungal
and mycobacterial pathogens and the toxins they produce.
ENDOGENOUS MEDIATORS OF INFLAMMATION
ANTIBODIES
CIRCULATING IMMUNE COMPLEXES
CYTOKINES
Fibrin
Amyloid
CRP
www.SystemicEnzymeSupport.org
Total Burden of Inflammatory Mediators
Collectively, mediators of inflammation can
result in immune dysregulation.
Proper immunomodulation promotes the
binding to, and removal of excessive
mediators of inflammation.
Protein Debris
© 2009 Joseph J Collins, RN, ND
13
Systemic Enzyme Formulation
Wobenzym® is composed of 270mg of bromelain, 300 mg of
rutoside trihydrate (rutin) and 144 mg of trypsin per three pH
resistant enteric coated tablets.
Bromelain: A cysteine endopeptidase (breaks peptide
bonds inside protein molecules) from the stem of the
pineapple plant (Ananas comosus). It is distinct from
the bromelain found in the pineapple fruit.
[1,2,3]
Trypsin: Trypsin is an animal serine endoproteinase
which breaks peptide bonds inside protein molecules.
[1,2,3]
Rutosid: A glycoside form of quercetin. Rutin
increases the strength of the walls of blood capillaries
and decreases pathologically increased vessel
permeability.[4,5]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
14
trans-mucosal Absorption
Wobenzym® PS is delivered through
tablets which have a special enteric
coating that can withstand the acid
environment in the stomach (very
important since enzymes can be
damaged by stomach acid). Once the
tablet has passed a safe distance from
the stomach acids, the tablet dissolves
and the enzymes are efficiently
absorbed by the mucosal membrane of
the intestine.
This process is most effective if the
tablets are taken away from meals (45
minutes before meals or 1 ½ hour after
meals).[1]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
15
α-2M Activation
After being absorbed, the
proteolytic enzymes
tryspin and bromelain,
from Wobenzym® PS, will
preferentially complex to
the bait region of alpha-2macroglobulin (a2M)) to
create α-2-macroglobulinprotease complexes.[1,2]
a2M, a high molecular weight plasma glycoprotein (8-10 % of total
serum protein) that functions as a binding, carrier, and targeting
protein. It binds host or foreign peptides and particles, thereby
serving as humoral defense barriers against pathogens in both the
plasma and the tissue.[3]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
16
Binding the Mediators of Inflammation
This trapping of 2 protease molecules from Wobenzym® into the
a2m changes the configuration of α-2-macroglobulin so that the
newly activated α-2-macroglobulin-protease complex now
has increased capacity for binding excessive interstitial and
intravascular cytokines, immunoglobulins, fibrin, CRP, amyloid
beta proteins, cell debris, and proteins damaged by oxidative
stress and glycosylation.[1,2,3,4,5,6,7,8,9,10,11]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
17
Clearance of α-2M-Protease-MI Complexes
Wobenzym® PS increases alpha-2-macroglobulin-proteinase
complexes, which are activated for receptor mediated endocytosis
and are readily removed by hepatic α-2M-receptors (α-2M-R), as well
as other cells expressing α-2M-R, such as macrophages. [1]
The alpha 2-macroglobulin-proteinase complexes promote
macrophage locomotion and chemotaxis, such that the activated
alpha 2-macroglobulin-proteinase complexes and the inflammatory
mediators bound to the complex are cleared from the circulation
very quickly by macrophages. [2,3]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
18
RESTORATION OF HEALTHY BIOMARKERS
Based on clinical studies, use of Wobenzym® results in the
following changes in mediators of inflammation:
Decreased Erythrocyte Sedimentation Rate[1,2,3,4,5,6]
Decreased C-Reactive Protein Levels [7,8,9]
Decreased Circulating Immune Complex Levels
[10,11,12,13,14,15,16,17,18,19]
Normalization of Cytokine Levels [21,21,22,23]
Normalization of Immunoglobulins (IgG, IgE, IgA, IgM) [24,25,26]
Restore Normal Fibrinolytic Activity [27,28]
Increased Amyloid Catabolism [29,30,31,32,33,34]
www.SystemicEnzymeSupport.org
© 2009 Joseph J Collins, RN, ND
19
Clinical Applications
Wobenzym® formulations are clinically effective in a broad range of
degenerative conditions due to its immunomodulatory, antiinflammatory, anti-edema, analgesic, fibrinolytic, thrombolysis, antitumor and antioxidant properties. Dozens of randomized, blinded and
placebo studies have evidenced that the specific formulation can be used in
various clinical specialties, including the following:
Andrology, Men’s Health
Arthritis, Rheumatology
Osteoarthritis
Rheumatoid Diseases
Reactive arthritis
Fibromylagias
Cardiology
Dentistry
Diabetology
Hepatology
www.SystemicEnzymeSupport.org
Immunology/Infectious Diseases
Lymphology
Nephrology
Neurology
Oncology
Otolaryngology
Pulmonology
Traumatology, Surgery
Urology
Vascular Medicine
© 2009 Joseph J Collins, RN, ND
20
Learn More About Wobenzym®
Professional Posters
digital copies of posters are on-line
www.SystemicEnzymeSupport.org
• Tutorial on Systemic Enzyme Support
• Conditions Treated with Systemic Enzymes
• Clinical Research Summaries and Abstracts
• Professional Articles (Technical)
• Dosage Guidelines
• Presentations
• Contact Info
This presentation (references in note section) is available
at: www.SystemicEnzymeSupport.org/presentations/
www.SystemicEnzymeSupport.org